![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the divestment, Nestle sells its peanut-allergy treatment business to stallergenes greer, including Palforzia (peanut allergen powder-dnfp), an oral immunotherapy treatment approved for the mitigation of allergic reactions, including anaphylaxis.
Lead Product(s): Peanut Allergen Powder-dnfp
Therapeutic Area: Immunology Product Name: Palforzia
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Nestle
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Divestment September 04, 2023
Details:
Staloral Staloral Birch is a sublingual solution of allergen extracts for AIT. It is indicated in the treatment of seasonal or perennial allergic rhinitis, rhino-conjunctivitis and mild to moderate allergic asthma
Lead Product(s): Birch Pollen Extract
Therapeutic Area: Immunology Product Name: Staloral Birch
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2023
Details:
Study results were consistent across all age groups showed a reduction of risk of asthma onset of more than 20% observed in patients undergoing treatment with sublingual liquid AIT and symptomatic drugs versus patients treated with symptomatic drugs only.
Lead Product(s): Allergen Extract
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Staloral
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator:
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 02, 2022
Details:
The STAGR320 phase III clinical trial, which included 1,600 patients from 231 participating investigative sites in 13 countries, assessed the treatment of HDM-induced allergic rhinitis in adult and adolescent patients.
Lead Product(s): House Dust Mite Allergen Extracts
Therapeutic Area: Immunology Product Name: Actair
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 09, 2021